| 12/04/2020 |
Consolidated Financial Results for the 2nd Quarter of the Fiscal Year Ending March 31, 2021(IFRS) |
| 11/11/2020 |
FY2021/3 H1, Presentation (Apr.1 to Sep.30 2020) |
| 11/11/2020 |
FY2021/3 H1, Supplementary Material(Apr.1 to Sep.30 2020) |
| 09/04/2020 |
Consolidated Financial Results for the 1st Quarter of the Fiscal Year Ending March 31, 2021(IFRS) |
| 08/11/2020 |
Year Ending March 31, 2021 Results of 1st Quarter Settlement of Accounts Supplementary Material (Apr.1 to Jun.30 2020) |
| 07/30/2020 |
Notice on Acquisition of A Company to be Established to Take Over Generic Pharmaceutical Business from Teva Takeda Pharma Ltd. |
| 07/30/2020 |
Presentation Materials of Acquisition of Generic Pharmaceutical Business from Teva Takeda Pharma Ltd. |
| 06/22/2020 |
Consolidated Financial Results for the Fiscal Year Ended March 31, 2020 (IFRS) |
| 06/08/2020 |
The University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo Reach Basic Agreement on Collaborative R&D on Nafamostat Inhalation Formulation for Treatment of Novel Corona Virus Infection (COVID-19) |
| 06/01/2020 |
Notice of the 56th Ordinary General Meeting of Shareholders |
| 05/18/2020 |
Year Ended March 31, 2020 Results Settlement of Accounts Supplementary Material (Apr.1 2019 to Mar.31 2020) |
| 05/18/2020 |
F2019, ended March 2020 |
| 03/13/2020 |
Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2020 (IFRS) |
| 02/14/2020 |
FY2020/3 Q3, Supplementary Material(Apr.1 to Dec.31 2019) |
